Public Release: 

Insilico Medicine selected to present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

InSilico Medicine, Inc.

IMAGE

IMAGE: InSilico Medicine. view more

Credit: InSilico Medicine Inc.

Baltimore, MD, February 3rd, 2016 -- Insilico Medicine, Inc, one of the leaders in drug discovery and biomarker development for aging and age-related diseases, announced today it has been selected to present its research results at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the Breakers in Palm Beach, Florida. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, research institutions, and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year.

Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, "The theme of our Palm Beach Forum is a 'Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.' With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of Insilico Medicine research and scientific insights in aging research, geroprotectors discovery and biomarker development positions them to make a major contribution to extending healthy human longevity."

"We are honored to be selected to present our research at this unique event, and it is further recognition of our innovative approach to diagnosing, preventing and treating age-related diseases and aging itself," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. "We welcome the chance to interact with many of world's most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of over 200 leading family offices and foundations from around the world with combined assets of over $260 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.

###

About Insilico Medicine, Inc

Insilico Medicine aims to extend healthy human longevity while minimizing animal testing and engaging in cutting-edge aging research utilizing some of the recent advances in genomics and high-performance computing. It provides analytical services to biopharmaceutical companies, repurposes existing drugs and develops molecular biomarkers of aging and age-related diseases. Headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore it has R&D resources in Belgium, Poland, Russia and China employing 39 scientists worldwide. It is one of the leaders in artificial intelligence trained on some of the largest repositories of gene expression and pharmacological data. The company utilizes advanced signaling pathway analysis and a technique called deep learning to discover drugs that slow down or even reverse aging in various tissues. The company has over 150 research collaborators and since 2014 company's scientists published over 40 research publications in peer-reviewed journals.

Further information is available on the Company's website, http://www.insilicomedicine.com.

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year.

For more information: http://cavendishglobal.com

For Further Information Contact:

Alex Charlton
President, Cavendish Global
alex.charlton@cavendishglobal.com
Tel: +1-917-576-1435

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.